Opdivo (nivolumab) Market Report 2026

Opdivo (nivolumab) Market Overview

• The Opdivo (nivolumab) market growth in the historic period has been driven by approval of pd-1 inhibitors, rising global cancer burden • Market expansion is supported by expansion into new oncology indications, growth of combination therapy protocols • Growth Driver: Impact of Rising Non-Small Cell Lung Cancer Incidence on Opdivo (Nivolumab) Market Growth • Market Trend: Opdivo (Nivolumab) Market Growth Driven by FDA Approvals for Combination Therapies in NSCLC • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Opdivo (nivolumab) Market?

Opdivo (nivolumab) is a prescription medication that belongs to a class of drugs known as immune checkpoint inhibitors, specifically targeting programmed death-1 (PD-1) receptors. It is a type of immunotherapy used to treat various cancers by enhancing the body's immune system to detect and destroy cancer cells. The main types in the opdivo (nivolumab) market are 40 mg/4 ml, 100 mg/10 ml, and 240 mg/24 ml. The 40 mg/4 mL dosage of Opdivo is a lower concentration of the drug, designed to be administered to patients requiring a smaller dose, commonly used for specific treatment protocols or lower-weight patients. The various dosages include injection, solution, and others, and several demographics including adult and pediatric. The different applications include melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, classical hodgkin lymphoma (CHL), squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC), and others. The end-users encompass hospitals, clinics, and others.

What Is The Opdivo (nivolumab) Market Growth Forecast?

The opdivo (nivolumab) market size is expected to see strong growth in the next few years. It will grow to $12.13 million in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to expansion into new oncology indications, growth of combination therapy protocols, increasing biomarker based patient selection, rising cancer diagnosis rates, increased oncology healthcare spending. Major trends in the forecast period include expanding use of immune checkpoint inhibitors, rising adoption of combination immunotherapy regimens, growth in pd-1 based cancer treatments, increased use across multiple cancer indications, focus on long term survival outcomes.

Global Opdivo (nivolumab) Market Segmentation

1) By Type: 40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL 2) By Dosage: Injection, Solution, Other Dosages 3) By Application: Melanoma, Non-small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Renal Cell Carcinoma (RCC), Other Applications 4) By End-User: Hospitals, Clinics, Other End Users

What Is The Driver Of The Opdivo (nivolumab) Market?

Increasing incidence of non-small lung cancer is expected to propel the growth of the opdivo (nivolumab) market going forward. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. The increasing incidence of non-small cell lung cancer (NSCLC) is primarily attributed to factors such as smoking, exposure to environmental pollutants, genetic mutations, and a family history of cancer. Opdivo works by blocking the PD-1 receptor on immune cells, thereby enhancing the body's immune response to recognize and attack cancer cells. For example, in 2024, the American Cancer Society, a US-based health organization, reported that 234,580 new cases of lung cancer were diagnosed in the US, with 80% of those being non-small cell lung cancer (NSCLC), marking an increase compared to 2023, when 238,340 people were diagnosed with lung cancer. Thus, increasing incidence of non-small lung cancer is driving the growth of the opdivo (nivolumab) industry.

Key Players In The Global Opdivo (nivolumab) Market

Major companies operating in the opdivo (nivolumab) market are Bristol-Myers Squibb, Ono Pharmaceutical

Global Opdivo (nivolumab) Market Trends and Insights

Major companies operating in the opdivo (nivolumab) market are focusing on developing advanced combination therapies to enhance treatment efficacy, overcome resistance mechanisms, and broaden applications across multiple cancer types. Combination therapy refers to the strategic use of Opdivo (nivolumab) alongside other agents, such as chemotherapy, to provide a more comprehensive treatment approach for advanced cancer patients. For instance, in October 2024, the Food and Drug Administration, a US-based federal agency, approved Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment, followed by single-agent nivolumab as adjuvant therapy after surgery, for adults with resectable non-small cell lung cancer who do not have known EGFR or ALK mutations. This approval allows Opdivo to be used both before and after surgery, enhancing therapeutic outcomes for eligible patients.

What Are Latest Mergers And Acquisitions In The Opdivo (nivolumab) Market?

In June 2024, I-Mab, a US-based biotechnology company focused on developing innovative immunotherapies for cancer, entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate bispecific antibody givastomig. Through this partnership, I-Mab aims to evaluate its investigational Claudin 18.2 x 4-1BB bispecific antibody, givastomig, in combination with Opdivo (nivolumab) and standard chemotherapy regimens (FOLFOX or CAPOX) as a potential first-line treatment for patients with advanced Claudin 18.2-positive gastric and esophageal cancers. Bristol Myers Squibb is a US-based pharmaceutical company that manufactures Opdivo (nivolumab).

Regional Insights

North America was the largest region in the 0pdivo (nivolumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Opdivo (nivolumab) Market?

The opdivo (nivolumab) market consists of sales of monotherapy and combination therapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Opdivo (nivolumab) Market Report 2026?

The opdivo (nivolumab) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the opdivo (nivolumab) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.